Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) Short Interest Update

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) saw a significant increase in short interest in March. As of March 31st, there was short interest totaling 236,224 shares, an increase of 19.0% from the March 15th total of 198,425 shares. Based on an average daily volume of 105,134 shares, the days-to-cover ratio is presently 2.2 days. Currently, 1.8% of the company’s stock are sold short.

Institutional Investors Weigh In On Kairos Pharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. FNY Investment Advisers LLC purchased a new position in shares of Kairos Pharma in the third quarter worth about $27,000. XTX Topco Ltd grew its holdings in Kairos Pharma by 290.8% during the fourth quarter. XTX Topco Ltd now owns 48,494 shares of the company’s stock worth $34,000 after acquiring an additional 36,086 shares during the period. Finally, Two Sigma Investments LP acquired a new stake in Kairos Pharma during the third quarter worth about $54,000.

Kairos Pharma Stock Performance

KAPA stock traded up $0.00 during trading on Friday, reaching $0.61. 50,983 shares of the company traded hands, compared to its average volume of 76,631. The business has a 50 day simple moving average of $0.60 and a 200 day simple moving average of $0.79. Kairos Pharma has a 12 month low of $0.40 and a 12 month high of $2.11. The company has a market capitalization of $13.09 million, a price-to-earnings ratio of -2.04 and a beta of 1.97.

Kairos Pharma (NYSEAMERICAN:KAPA) last released its quarterly earnings results on Tuesday, March 31st. The company reported ($0.07) EPS for the quarter.

About Kairos Pharma

Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical?stage biopharmaceutical company focused on developing small?molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full?length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics.